Lupus Nephritis Market Expected to Grow as Novel Therapies Enter Clinical Trials
The global lupus nephritis market is projected to grow significantly by 2034, with the United States accounting for over 80% of the current $1.12 billion market share across major regions.
Promising Pipeline for Mantle Cell Lymphoma Treatment: 22+ Therapies Under Development by 20+ Companies
DelveInsight's latest report reveals a robust pipeline with 20+ companies developing 22+ therapies for mantle cell lymphoma, highlighting significant advancement in treatment options for this rare blood cancer.
Novel Therapies Transform Rheumatology Landscape in Early 2025
FDA regulatory actions in Q1 2025 include approval of Celltrion's denosumab biosimilars and Fast Track designation for CAR-T therapies targeting lupus, expanding treatment options for autoimmune conditions.
Lupus Nephritis Clinical Trial Landscape Shows Active Development
The lupus nephritis clinical trial pipeline is robust, featuring over 30 companies developing more than 35 therapies.
Gene Therapy Advances: From FDA Clearances to Clinical Trial Progress in Early 2025
The FDA cleared United Therapeutics' UKidney for US trials, a gene-edited porcine kidney product intended for end-stage renal disease via xenotransplant.
Adicet Bio's ADI-001 Receives FDA Fast Track for Refractory SLE, Expands Autoimmune Pipeline
Adicet Bio's ADI-001 receives FDA Fast Track designation for refractory systemic lupus erythematosus (SLE) with extrarenal involvement, expediting its development.
Adicet Bio Initiates Phase 1 Trial of ADI-270, a Novel CAR T-cell Therapy for Advanced Kidney Cancer
Adicet Bio has commenced a Phase 1 clinical trial for ADI-270, an allogeneic gamma delta CAR T-cell therapy, in patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC).
Adicet Bio Doses First Patient in Phase 1 Lupus Nephritis Trial with ADI-001
Adicet Bio has dosed the first lupus nephritis (LN) patient in its Phase 1 clinical trial evaluating ADI-001, an allogeneic gamma delta CAR T cell therapy.
Adicet Bio Doses First Patient in Phase 1 Lupus Nephritis Trial of ADI-001
Adicet Bio has dosed the first patient in its Phase 1 clinical trial of ADI-001 for lupus nephritis, marking a key step in autoimmune disease treatment.
Adicet Bio's ADI-001 Demonstrates Promising CAR T-Cell Activation in Autoimmune Diseases
Adicet Bio presented clinical biomarker data for ADI-001, an off-the-shelf gamma delta CAR T cell therapy, at the ACR Convergence 2024, showcasing its potential in treating autoimmune diseases.